Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | GCK | P35557 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6918617 | 0.87 | GCK (0.57) | GRM5NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL6919419 | 0.87 | NPC1 (0.66) | GRM5NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL6918101 | 0.82 | GRM5 (0.78) | GRM5NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL6928862 | 0.81 | GRM5 (0.72) | GRM5 | |
| SCHEMBL8797071 | 0.79 | NPC1 (0.62) | NPC1HPGDRAB9ASMN1; SMN2GCK | |
| SCHEMBL6918739 | 0.78 | RAB9A (0.66) | GRM5NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL6918266 | 0.77 | GRM5 (0.55) | GRM5NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3178619 | 0.76 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4756204 | 0.76 | SMN1; SMN2 (0.52) | NPC1HPGDRAB9ASMN1; SMN2GCK | |
| SCHEMBL1486126 | 0.75 | GRM5 (0.81) | GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796295-B2 | Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110152299-A1 | SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-23 | — | — | US | disclosed |
| WO-2011035209-A1 | SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSTIY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152299-A1 | SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRIN2A | GRM5 1/4885NPC1 2582/4885HPGD 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.